logo
Finwire

Finwire

Double Bond decides on SEK 10.2 million rights issue

The pharmaceutical company Double Bond Pharma has decided on a rights issue of approximately SEK 10.2 million before issue costs. The issue is covered to approximately 45.1 percent by subscription undertakings from, among others, two major shareholders.

The subscription price is SEK 0.11 per share, and twelve existing shares entitle the holder to subscribe for five new B shares. The subscription period runs from 18 November to 2 December. If fully subscribed, the dilution amounts to approximately 29.41 percent of the shares. The last trading day including the right to receive subscription rights is 12 November, and the first trading day excluding the right is 13 November.

The company assesses that existing working capital is insufficient for the next twelve months. The funds will primarily finance ongoing operations, partner discussions and preparations for clinical trials of the drug candidate SI-053.

Up to SEK 3 million of the issue proceeds may be used to offset existing loans. Issue costs are estimated at a maximum of SEK 0.3 million.

Share this post

Verifierad av MonsterInsights